Who knows. What we do know is someone intimately familiar with the data and its potential utility is no longer bound by any prior contractual obligations as to its use. I doubt this will end well, but i am a cynic.

What makes it a great outcome?

The principle is that employees matter more than shareholders: wiping out shareholders to save jobs is the greater good even if it enriches a nefarious or incompetent executive. Many retail investors are shocked to learn in their first bankruptcy how low they are in the pecking order when a company goes under.

The alternative is just to not make stupid investments in the first place. The shareholders knew (or should have known) the risk. If "dumb money" hasn't purchased the stock then the CEO wouldn't have been able to burn their capital.

Very few companies have CEOs that actually have the voting shares to run their own company to the ground to buy it privately.

Wojcicki was actually able to stand against the rest of the board to bring this company down to bankruptcy level because of her 49% voting shares

She wasn't rewarded, she asked to take it private twice because it was going to go bankrupt, board said no both times, now she has to pay 7.5x her last offer to them.

I think you're misunderstanding it as if the company endogenously failed due to missteps on her end, which sort of trivially can't be the case, there's a very defined product here where you can charge more for the output than the input. Thing is, investors / board didn't wanna run that sort of business, apparently.

If it clearly had more assets than the cost more people would bid for it at auction

And then what? So you find a full genome test provider, and now you have a full array result: What do you then do with it that doesn't violate your privacy?

Isn't the real prize the library of personally-identified samples preserved in their "biobank" and not the methodologies or analysis they've applied to it so far...

I rarely used the 23andme website for much of anything and always used it to export into Promethease.

They have the freezers filled with biological material that could be resequenced though. Or not?

They decided to try to be a pharma company instead of a diagnostics company. The microarray tech was obsolete, but they did have a lot of data. The problem is that being a pharmaceutical company is very difficult. I always question why they wanted to play in early pipeline rather than using their data to have an edge in later stage acquisitions. Perhaps they felt that running later stages of development and commercialization was too difficult, risky, and capital intensive; but if so then they probably had no business trying to sell drugs in the first place.

I thought they all gave you the option to delete your data? That's effectively the same.